Access Bio (XKRX:950130) ROCE % : 3.12% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Access Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Access Bio's annualized ROCE % for the quarter that ended in Mar. 2024 was 3.12%.

Access Bio ROCE % Historical Data

The historical data trend for Access Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio ROCE % Chart

Access Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-31.41

84.37

128.67

94.65

-0.32

Access Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															32.75	-18.05	-8.29	-9.09	3.12

Access Bio ROCE % Calculation

Access Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2168.632	/	( ( (885479.769 - 196304.207)	+	(691136.495 - 44016.853) )	/ 2 )
	=	-2168.632	/	( (689175.562	+	647119.642)	/ 2 )
	=	-2168.632	/	668147.602
	=	-0.32 %

Access Bio's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	20519.632	/	( ( (691136.495 - 44016.853)	+	(712494.883 - 43367.145) )	/ 2 )
	=	20519.632	/	( ( 647119.642	+	669127.738 )	/ 2 )
	=	20519.632	/	658123.69
	=	3.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Access Bio (XKRX:950130) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Access Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Access Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio (XKRX:950130) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Clyde Road, Suite A, Somerset, NJ, USA, 08873

Website

http://www.accessbio.net

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio (XKRX:950130) Headlines

No Headlines